Addendum: Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy

PDF  |  How to cite

Oncotarget. 2022; 13:1215-1215. https://doi.org/10.18632/oncotarget.28296

Metrics: PDF 101 views  |   ?  

Rajnish Nagarkar1, Darshana Patil2, Sewanti Limaye3, Pradip Devhare2, Ashwini Ghaisas2, Navin Srivastava2, Sachin Apurwa2, Sanket Patil2, Jinumary John2, Zarrine Raazi2, Aditya Shreenivas4, Janani Sambath5,6, Ajay Srinivasan2, Prashant Kumar2,5,6, Dadasaheb Akolkar2 and Rajan Datar2

1HCG Manavata Cancer Centre, Nasik, Maharashtra, India
2Datar Cancer Genetics Limited, Nasik, Maharashtra, India
3Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
4Department of Medical Oncology, Medical College Wisconsin, WI, USA
5Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India
6Manipal Academy of Higher Education, Manipal, Karnataka, India

Published: November 2, 2022

Copyright: © 2022 Nagarkar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The patient has previously consented to publication of de-identified findings.

Original article: Oncotarget. 2020; 11:4195–4200. DOI: https://doi.org/10.18632/oncotarget.27793

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28296